| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 6th February 2021 | Richard Hague | 10,091 | Payment by withholding | $1.16 | $11,705.56 |
| 16th January 2021 | Richard Hague | 12,456 | Payment by withholding | $1.08 | $13,452.48 |
| 26th December 2020 | Richard Hague | 5,283 | Payment by withholding | $0.70 | $3,698.10 |
| 10th November 2020 | Raymond J Land | 3,446 | Open or private sale | $36.77 | $126,709.42 |
| 30th October 2020 | Thomas Finnerty | 666 | Payment by withholding | $32.62 | $21,724.92 |
| 16th October 2020 | Richard Hague | 10,546 | Payment by withholding | $1.07 | $11,284.22 |
| 8th October 2020 | Richard Hague | 2,563 | Payment by withholding | $1.12 | $2,870.56 |
| 1st October 2020 | Susan L N Vogt | 14,133 | Grant/award etc. | $0.00 | |
| 28th September 2020 | Richard Hague | 5,283 | Payment by withholding | $1.04 | $5,494.32 |
| 3rd September 2020 | John B Iii Henneman | 9,310 | Grant/award etc. | $0.00 |
Anika Therapeutics
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 5/10.
Anika Therapeutics, Inc. is an orthopedic and regenerative medicines company. The company develops, manufactures and commercializes therapeutic products for pain management, tissue regeneration, and wound healing. Its products are based on hyaluronic acid, a natural chemical occurring, biocompatible polymer found throughout the body.
Ticker: ANIK
Sector: Healthcare
Industry: Biotechnology
SEC Central Index Key (CIK): 898437
Employees:
Exchange: NASDAQ
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
Goodwill Impairment Loss of $18 M for the period Jan 2020 to Jun 2020 in the context of all up
Fundamentals
Cash at Carrying Value: $117 M (-25%)
Marketable Securities, Current: $28 M (0%)
Inventory, Net: $46 M (0%)
Assets, Current: $221 M (-5%)
Property, Plant and Equipment, Net: $53 M (3%)
Other Assets, Noncurrent: $13 M (79%)
Assets: $441 M (33%)
Accounts Payable, Current: $6 M (60%)
Liabilities, Current: $28 M (71%)
Other Liabilities, Noncurrent: $843 Th (136%)
Common Stock, Value, Issued: $142 Th (0%)
Common Stock, Shares, Issued: $14 Th (0%)
Additional Paid in Capital, Common Stock: $51 M (3%)
Retained Earnings (Accumulated Deficit): $244 M (0%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $6 M (-1%)
Stockholders' Equity (Parent): $288 M (0%)
Liabilities and Equity: $441 M (33%)
Revenue: $31 M (0%)
Cost of Revenue: $17 M (-45%)
Research and Development: $5 M (-57%)
Operating Income/Loss: $10 M (290%)
Provision for income taxes: $2 M (0%)
EPS (basic): $0.54 (315%)
EPS (diluted): $0.54 (315%)
